인도의 여성 건강 치료 시장 규모는 2024년 19억 8,000만 달러에 달했고, 2032년에 53억 달러에 이를 것으로 예측됩니다. 2025년-2032년의 예측 기간에 CAGR 13.10%를 나타낼 것으로 예상됩니다. 시장은 최근 기술의 발전과 효율적인 솔루션에 대한 수요가 증가함에 따라 크게 성장하고 있습니다. 이 나라 시장 확대의 주요 촉진요인 중 하나는 좌식 생활 방식과 변화하는 환경 조건으로 인해 인구의 생식 건강이 대부분 감소하고 있다는 점입니다.
2024년 6월 Orchid Pharma는 Cipla와 협력하여 복잡한 요로 감염(cUTI), 인공호흡기 관련 폐렴(VAP), 원내 폐렴(HAP) 치료제로 승인된 획기적인 복합 항생제, 세페핌-엔메타조박탐을 출시했습니다. 이 협력은 이 치료법이 인도 전역에 널리 보급되도록 보장했습니다. 또한, 이 제휴에 의해 Orchid의 의약품 개발 능력과 Cipla의 유통망이 조합되어, 이 생명을 구하는 치료제이 효율적으로 의료 종사자에게 전달될 수 있게 되었습니다.
이 보고서는 인도의 여성 건강 치료 시장에 대한 조사 분석을 통해 시장 규모와 예측, 시장 역학, 주요 기업 현황 등을 제공합니다.
India women's health therapeutics market is projected to witness a CAGR of 13.10% during the forecast period FY2025-FY2032, growing from USD 1.98 billion in FY2024 to USD 5.30 billion in FY2032. India market for women's health therapeutics has grown significantly because of recent advancements in technologies and the growing demand for efficient solutions. One of the primary factors propelling market expansions in the country is most of the population's declining reproductive health owing to the sedentary lifestyles and shifting environmental conditions.
In June 2024, Orchid Pharma partnered with Cipla to launch Cefepime-Enmetazobactam, a breakthrough antibiotic combination approved for treating complicated Urinary Tract infections (cUTI), Ventilator-Associated Pneumonia (VAP), and Hospital-Acquired Pneumonia (HAP). This collaboration ensured widespread distribution of this treatment across India. In addition, the partnership combined Orchid's drug development capabilities with Cipla's distribution network, ensuring that this life-saving medication reaches healthcare providers efficiently.
Government Initiatives Fueling the Market Growth
Support from the government is crucial for the growth of women's health therapeutics market in India. Women's healthcare access, affordability, and awareness are receiving attention at the policy level, and many programs have been initiated to aid this. For example, Pradhan Mantri Surakshit Matritva Abhiyan (PMSMA) guarantees free prenatal checkups, while the adolescent health program focuses on the RKSK. Furthermore, the Ayushman Bharat Scheme enables fast financial aid to women facing costly procedures, including cancer treatments. Other regulations, such as drug price limits set by the NPPA, increase affordability of important drugs and medicines. There are also efforts to increase self-sufficiency in pharmaceuticals through the Production-Linked Incentive (PLI) Scheme, which promotes local businesses instead of foreign ones. The surge in funding directed toward women's health studies, the opening of new Janaushadhi Kendras, and changes in policy that favor menstrual and reproductive health care amplify the sales potential further. Such policy support guarantees usage of women healthcare services in India for both urban and rural areas, which is likely to bring forth many solutions for women's health issues. For instance, launched in Odisha, this universal health coverage program provides annual health coverage of USD 5,726 per family and USD 8,016 for female members. The scheme aims to enhance healthcare accessibility, particularly benefiting women in the state
Scientific Innovations Boosting Market Growth
Scientific research is a key driver in Women health therapeutics, resulting in sophisticated treatments, improved diagnostic technology, and targeted therapies. There has been an increase in government and private funding leading to faster paced research in endometriosis, polycystic ovarian syndrome (PCOS), infertility, and menopausal research. The rise of precision medicine and biotechnology has facilitated the development of personalized hormonal treatment for reproductive disorders, as well as non-invasive diagnostic tools. There has also been considerable progress in stem cell therapies and gene editing alongside drug delivery systems using nanotechnology for improving women's health in India. The Indian Council of Medical Research (ICMR) is collaborating with private pharma companies on clinical trials of new cancer therapies, fertility drugs, and HPV vaccines. These investments in R&D enable the advancement of woman healthcare by improving the efficacy, affordability, and accessibility of these treatments. For example, In December 2024, Novo Nordisk India advocated for an expedited launch of its weight-loss drug for women, called Wegovy, to compete with Eli Lilly's anticipated introduction of Mounjaro in 2025. Both drugs are GLP-1 receptor agonists, highly sought after for weight management.
Rising Incidence of Cancer Fueling the Market Growth
The increasing occurrence of cancer, particularly among women in India, is one of the major factors for the growth of the women's health therapeutics market. There is an increase in breast, cervical, ovarian, and endometrial cancers due to changes in lifestyle, genetic factors, and diagnosis at a later stage. As per the National Cancer Registry Programme (NCRP), the number of breast cancer cases in India has increased twofold over the past ten years, making it the most prevalent cancer among women. The surge in cases of HPV-induced cervical cancer recently prompted the government to implement vaccination drives across the country which stimulated demand for HPV vaccines. There is a growing pharmaceutical investment in oncology drugs due to the advances in targeted therapies, immunotherapy, and hormone therapy. The introduction of awareness programs on cancer, early detection, and increased access to cancer treatment through Ayushman Bharat is causing a rise in the need for novel and cost-effective women-centric cancer therapeutics. This growing burden of disease amplifies the demand for greater research, improved diagnostic tools, and more sophisticated treatment options. According to Observer Research Foundation, the number of cases of breast cancer increased steadily from 200,218 in 2019 to 221,579 in 2023; at the same time, the number of deaths from the disease increased from 74,481 to 82,429 in India. Even while incidence is far higher than fatality, mortality rates have been steadily rising, which suggests problems with early detection, access to treatment, and efficient management.
Future Market Scenario (FY2025 - FY2032F)
Many factors claim the growth of India women's health therapeutics market. Technological advancements give faster and more accurate results leading us to early diagnosis. Opportunity also lies in the increasing number of fertility concerns that the population is facing today. Promising initiatives of our government that provide healthcare infrastructure, funds to carry on research and development on a large scale, and a reliable distribution channel that ensures the solution reaches everyone is testimonial. For instance, from primary healthcare facilities to sophisticated tertiary care hospitals, India currently has a vast healthcare infrastructure. One of the biggest healthcare systems in the world is expected to grow because of increased public and private sector investment. To increase access to high-quality healthcare for a larger portion of the population, developers are currently collaborating with healthcare providers to build cutting-edge facilities in tier 2 and tier 3 cities as well as metropolitan areas.
Key Players Landscape and Outlook
Key players in the women's health therapeutics industry utilize strategies such as mergers, acquisitions, partnerships, and new product launches to improve their services and competitiveness. Such efforts will propel significant growth in the market, allowing big-cap industry players to increase their presence and, therefore, find new opportunities in this market.
For instance, Pradhan Mantri Bharatiya Janaushadhi Pariyojana (PMBJP) is an initiative which has expanded significantly, offering over 2,000 types of generic drugs and more than 300 surgical products by 2024. Notably, the scheme includes the "Janaushadhi Suvidha Oxy-Biodegradable Sanitary Napkin," providing affordable sanitary products to women across the country.
All segments will be provided for all regions and countries covered
Companies mentioned above DO NOT hold any order as per market share and can be changed as per information available during research work.